{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011327","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.546180+00:00","generated_at":"2026-06-04T08:10:58.454845+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Provectus Biopharmaceuticals Names Dominic Rodrigues Principal Executive Officer; Bruce Horowitz Resigns","bullets":["Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.","The termination agreement includes an initial $250,000 payment and a second payment of $258,000 if paid before June 30, 2024, otherwise $500,000.","Dominic Rodrigues was appointed as chief operations consultant and principal executive officer with a monthly fee of $20,000.","The company agreed to continue D&O insurance for Horowitz for two years and Horowitz agreed to a five-year standstill.","The termination agreement includes mutual releases, confidentiality reaffirmation, and non-disparagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011327","json":"https://secwatch.observer/filing/0001493152-24-011327.json","markdown":"https://secwatch.observer/filing/0001493152-24-011327.md","text":"https://secwatch.observer/filing/0001493152-24-011327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:10:58.454845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08841473e0","claim":"Dominic Rodrigues was appointed as Chief Operations Consultant at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"the Board retained Dominic Rodrigues as the Company’s chief operations consultant.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operations Consultant"}],"fact_type":"executive_change"},{"claim_id":"65456737d7","claim":"Bruce Horowitz resigned as Chief Operating Officer at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"b2400c61ba","claim":"Bruce Horowitz resigned as Director at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}